Publication:
Humoral response to BNT162b2 and coronaVac in patients undergoing maintenance hemodialysis: A multicenter prospective cohort study

Simple item page
dc.contributor.authorTUĞCU, MURAT
dc.contributor.authorTUĞLULAR, ZÜBEYDE SERHAN
dc.contributor.authorsMİRİOĞLU Ş., KAZANCIOĞLU R., Cebeci E., EREN N., Sakaci T., Alagoz S., Tugcu M., TUĞLULAR Z. S., SÜMBÜL B., Seyahi N., et al.
dc.date.accessioned2023-01-23T07:39:04Z
dc.date.available2023-01-23T07:39:04Z
dc.date.issued2023-01-01
dc.description.abstractIntroduction: Data regarding inactivated vaccines for SARS-CoV-2 in patients undergoing maintenance hemodialysis (MHD) are limited. We aimed to investigate humoral responses induced by CoronaVac compared to BNT162b2 in this population. Methods: In this multicenter prospective cohort study, adult patients undergoing MHD who lacked a history of COVID-19 and decided to get vaccinated with BNT162b2 or CoronaVac were enrolled. Participants provided serum samples before, 1 and 3 months after 2 doses. Anti-SARS-CoV-2 IgG antibodies against receptor-binding domain of the virus were measured, and levels >= 50 AU/mL were considered as positive. Breakthrough infections and adverse events were recorded. Results: Ninety-two patients were included, 68 (73.9%) of whom were seronegative at baseline. BNT162b2 and CoronaVac were administered in 38 (55.9%) and 30 (44.1%) patients. At 1 month, seropositivity was 93.1% in BNT162b2 and 88% in CoronaVac groups (p = 0.519). Quantitative antibody levels were significantly higher in BNT162b2 (p < 0.001). At 3 months, both seropositivity (96.4% and 78.3%, p = 0.045) and antibody levels (p = 0.001) remained higher in BNT162b2 compared to CoronaVac. Five patients (7.4%) experienced breakthrough COVID-19. Adverse events were more frequent with BNT162b2, although all of them were mild. Multiple linear regression model showed that only vaccine choice (BNT162b2) was related to the humoral response (beta = 0.272, p = 0.038). Seropositive patients at baseline (n = 24) had higher antibody levels at any time point. Conclusions: BNT162b2 and CoronaVac induced humoral responses in naive patients undergoing MHD, which were more robust and durable for 3 months after BNT162b2. Both vaccines created high antibody levels in patients who were seropositive at baseline.
dc.identifier.citationMİRİOĞLU Ş., KAZANCIOĞLU R., Cebeci E., EREN N., Sakaci T., Alagoz S., Tugcu M., TUĞLULAR Z. S., SÜMBÜL B., Seyahi N., et al., "Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study", NEPHRON, 2023
dc.identifier.doi10.1159/000528170
dc.identifier.issn1660-8151
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/d3f05595-b84b-43c0-8951-d68df110d548/file
dc.identifier.urihttps://hdl.handle.net/11424/285723
dc.language.isoeng
dc.relation.ispartofNEPHRON
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectNefroloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectNephrology
dc.subjectHealth Sciences
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectUROLOGY & NEPHROLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectÜroloji
dc.subjectUrology
dc.subjectCOVID-19
dc.subjectDialysis
dc.subjectHemodialysis
dc.subjectSARS-CoV-2
dc.subjectVaccine
dc.subjectDIALYSIS PATIENTS
dc.subjectMESSENGER-RNA
dc.subjectKIDNEY-TRANSPLANT
dc.subjectIMMUNOGENICITY
dc.subjectMORTALITY
dc.subjectVACCINES
dc.titleHumoral response to BNT162b2 and coronaVac in patients undergoing maintenance hemodialysis: A multicenter prospective cohort study
dc.typearticle
dspace.entity.typePublication
local.avesis.idd3f05595-b84b-43c0-8951-d68df110d548
local.indexed.atWOS
local.indexed.atPUBMED
relation.isAuthorOfPublicationafd936cf-9aca-4324-85da-41283a9ec64c
relation.isAuthorOfPublication3ea0c6f9-3408-46b6-b382-144ccbf7bc72
relation.isAuthorOfPublication.latestForDiscoveryafd936cf-9aca-4324-85da-41283a9ec64c

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
6.pdf
Size:
205.04 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs